IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform
May 17 2022 - 7:00AM
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical
company focused on the discovery and development of gamma-delta T
cell therapies, today announced data emerging from the Company’s
recently unveiled iPSC-based gamma-delta T cell platform. iPSCs
represent a significant step toward next generation approaches of
cellular manufacturing for true allogeneic ‘off-the-shelf’ innate
cell therapies, and further broaden the Company’s capabilities
around the expansion and genetic engineering of gamma-delta T
cells.
“Our iPSC program is innovative and could provide a potentially
unlimited ‘off-the-shelf’ source of gamma-delta T cells,” said
Lawrence Lamb Ph.D., CSO, and co-founder of IN8bio. “This provides
another tool to advance IN8bio’s gamma-delta T cell-based
approaches to target cancer. Our team has achieved a number of
firsts and are advancing iPSCs as an approach to Vd1+ based
gamma-delta T cell therapies in addition to our ongoing work with
Vd2+ cells. Our team continues to lead in the development of
gamma-delta T cell therapies as we work towards transforming hope
into reality for cancer patients.”
IN8bio presented data from the iPSC platform during both podium
and poster presentations at the ASGCT 25th Annual Meeting in
Washington, DC, on May 16, 2022. These data demonstrated that donor
cells could be programmed into iPSCs, expanded, then differentiated
in a stepwise feeder-free process into gamma-delta T cells. The
platform encompasses the ability to perform directed
differentiation to both Vd1+ and Vd2+ cell sub-types. The iPSC
derived gamma-delta T cells were characterized both
morphologically, through cell surface markers, as well as
functionally, through killing assays. The differentiated cells were
shown to have normal karyotypes and robust cytotoxicity, which may
exceed that of patient or donor derived cells. The Company also
demonstrated genetic engineering of the iPSC gamma-delta T cells
through the transduction of a novel CAR construct targeting
chlorotoxin and incorporating IN8bio’s drug resistant immunotherapy
(DRI) technology.
The Company will be hosting a Research & Development
Workshop on May 17, 2022 from 6:00-8:00 p.m. EDT to provide company
updates on its strategy and pipeline. The discussion will cover
preclinical data from the iPSC platform, a review of clinical
programs along with details on the Phase 1b/2 trial design in
relation to the Company’s anticipated investigational new drug
application (IND) filing. Guest speakers will include Dieter
Kabelitz, M.D., from the University of Kiel in Germany, a world
recognized expert on gamma-delta T cells and Bruce Levine, Ph.D.,
from the University of Pennsylvania and the current President of
the International Society for Cell & Gene Therapy (ISCT), who
are both member of the company’s scientific advisory board. The
webcast can be accessed on the Events & Presentations page of
the Company’s website.
The ASGCT poster is available on the Events & Presentations
page of the IN8bio website:
https://investors.in8bio.com/news-events/events-presentations.
About IN8bioIN8bio is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of gamma-delta T cell product candidates for
solid and liquid tumors. Gamma-delta T cells are a specialized
population of T cells that possess unique properties, including the
ability to differentiate between healthy and diseased tissue.
IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and
genetically modified approaches to develop cell therapies, designed
to effectively identify and eradicate tumor cells.
IN8bio is currently conducting two investigator-initiated Phase
1 clinical trials for its lead gamma-delta T-cell product
candidates: INB-200 for the treatment of newly diagnosed
glioblastoma and INB-100 for the treatment of patients with
leukemia undergoing hematopoietic stem cell transplantation. IN8bio
also has a broad portfolio of preclinical programs focused on
addressing other solid tumor types. For more information about
IN8bio and its programs, please visit www.IN8bio.com.
Forward Looking StatementsThis press release
may contain forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by words such as
“aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”
“potential,” “seeks,” “will” and variations of these words or
similar expressions that are intended to identify forward-looking
statements, although not all forward-looking statements contain
these words. Forward-looking statements in this press release
include, but are not limited to, statements regarding the potential
of IN8bio’s iPSC-based gamma-delta T cell platform and its ability
to develop allogeneic cell therapies. IN8bio may not actually
achieve the plans, intentions or expectations disclosed in these
forward-looking statements, and you should not place undue reliance
on these forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations
disclosed in these forward-looking statements as a result of
various factors, including: risks related to the clinical
development of innovative technologies; risks to site initiation,
clinical trial commencement, patient enrollment and follow-up, as
well as IN8bio’s ability to meet anticipated deadlines and
milestones, presented by the ongoing COVID-19 pandemic;
uncertainties inherent in the initiation and completion of
preclinical studies and clinical trials and clinical development of
IN8bio’s product candidates; the risk that IN8bio may not realize
the intended benefits of its DeltEx platform; availability and
timing of results from preclinical studies and clinical trials;
whether the outcomes of preclinical studies will be predictive of
clinical trial results; whether initial or interim results from a
clinical trial will be predictive of the final results of the trial
or the results of future trials; the risk that trials and studies
may be delayed and may not have satisfactory outcomes; potential
adverse effects arising from the testing or use of IN8bio’s product
candidates; expectations for regulatory approvals to conduct trials
or to market products; IN8bio’s reliance on third parties,
including licensors and clinical research organizations; and other
important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, are
described in greater detail in the section entitled “Risk Factors”
in our Annual Report on Form 10-k filed with the Securities and
Exchange Commission (SEC) on March 17, 2022, as well as in other
filings IN8bio may make with the SEC in the future. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and IN8bio expressly disclaims any
obligation to update any forward-looking statements contained
herein, whether because of any new information, future events,
changed circumstances or otherwise, except as otherwise required by
law.
ContactsIN8bio, Inc.Kate Rochlin, Ph.D.+1
646.600.6438kmrochlin@in8bio.com
Investors:Solebury TroutDavid Buck+1
646.378.2927dbuck@soleburytrout.com
Media:Burns McClellan, Inc.Katie Larch / Robert
Flamm, Ph.D.klarch@burnsmc.com / rflamm@burnsmc.com
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Sep 2024 to Oct 2024
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Oct 2023 to Oct 2024